NASDAQ · WVE
Healthcare · Biotechnology
$3.63
Down-$0.01 (-0.27%)
Updated Oct 30, 2026, 4:43 AM
SID Score
3.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance · WVE
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
WVE closed at $3.63 after 21 trading sessions, down 6.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $3.75 | $3.86 | $3.60 | $3.63 | 3.59M |
| Oct 28, 2026 | $3.44 | $3.77 | $3.36 | $3.64 | 4.26M |
| Oct 27, 2026 | $3.55 | $3.55 | $3.235 | $3.45 | 4.2M |
| Oct 26, 2026 | $3.17 | $3.235 | $3.13 | $3.21 | 3.22M |
| Oct 23, 2026 | $3.33 | $3.34 | $3.12 | $3.18 | 2.66M |
| Oct 22, 2026 | $3.36 | $3.43 | $3.34 | $3.35 | 1.85M |
| Oct 21, 2026 | $3.42 | $3.48 | $3.35 | $3.37 | 2.17M |
| Oct 20, 2026 | $3.18 | $3.49 | $3.18 | $3.42 | 3.62M |
| Oct 19, 2026 | $3.15 | $3.19 | $3.08 | $3.17 | 1.87M |
| Oct 16, 2026 | $3.24 | $3.28 | $3.08 | $3.13 | 3.28M |
| Oct 15, 2026 | $3.13 | $3.23 | $3.08 | $3.19 | 3.35M |
| Oct 14, 2026 | $3.09 | $3.13 | $3.0399 | $3.09 | 2.83M |
| Oct 13, 2026 | $3.27 | $3.27 | $3.07 | $3.14 | 4.18M |
| Oct 12, 2026 | $3.46 | $3.46 | $3.27 | $3.28 | 2.26M |
| Oct 9, 2026 | $3.49 | $3.525 | $3.43 | $3.46 | 1.66M |
| Oct 8, 2026 | $3.48 | $3.51 | $3.365 | $3.47 | 2.66M |
| Oct 7, 2026 | $3.48 | $3.60 | $3.43 | $3.54 | 3.05M |
| Oct 6, 2026 | $3.78 | $3.815 | $3.4815 | $3.52 | 3.45M |
| Oct 5, 2026 | $3.81 | $3.88 | $3.705 | $3.75 | 3.51M |
| Oct 2, 2026 | $3.89 | $3.96 | $3.77 | $3.78 | 3.75M |
| Oct 1, 2026 | $3.95 | $4.07 | $3.775 | $3.88 | 5.42M |
The latest Smart Investors Daily articles mentioning WVE.
Company
Market Activity
Research & News
WVE research
Company profile and research snapshot.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 28, 2026 | Oppenheimer | Outperform | — |
| Oct 16, 2026 | William Blair | Outperform | — |
| Oct 15, 2026 | UBS | Buy | — |
| Oct 1, 2026 | Ladenburg Thalmann | Buy | — |
| Sep 23, 2026 | JP Morgan | Neutral | — |
No generated briefing is available yet.
Yahoo · Oct 22, 2026
WAVE Life Sciences (NASDAQ:WVE) outlined progress across its obesity-focused siRNA program and RNA editing pipeline during a Chardan discussion, with President and CEO Paul Bolno emphasizing the company’s chemistry platform, upcoming clinical studies and regulatory alignment for its alpha-1 antitryp
Yahoo · Oct 21, 2026
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 20, 2026
CAMBRIDGE, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, October 27, 2026, to review the company’s third quarter 2026 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors section
Yahoo · Oct 19, 2026
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced it will host a virtual Research Day on Wednesday, November 4, 2026 at 9:30 a.m. ET. During the event, Wave will share new data highlighting its differentiated RNA medicines platform, including its best-in-class chemistry, hepatic and extra-hepatic capabilities, and RNAi, RN
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning WVE.
